Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2023

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

7. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	June 30, 2023		December 31, 2022
Clinical and development costs	$	2,157	$	6,717
Manufacturing and quality costs		2,707		—
Payroll and payroll-related costs		11,688		14,709
Collaboration payable - related party (Note 16)		31,372		34,770
Facility and other		7,954		3,644
	$	55,878	$	59,840

As of June 30, 2023, the Company accrued a total of $3,850 payable to third parties for transaction and milestone payments resulting from the FDA approval of VOWST and subsequent commercial launch. This amount is included in the Facility and other category above.